Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval
September 19, 2016 at 14:27 PM EDT
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared higher by more than 80 percent Monday and hit a new 52-week high of $56.18. ...